Moreover, tumor-derived EVs enriched in TGFβ have been shown to inhibit IL-2-induced T-cell proliferation and to induce regulatory T cell (Treg) phenotype in acute myeloid leukemia (AML) [144], mesothelioma [145], and colorectal cancer [146]. This evidence concerns the gene TGFB1 and neoplasm.